Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

@article{Yoshida1999InterferonTR,
  title={Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.},
  author={Haruhiko Yoshida and Yasushi Shiratori and Mitsuhiko Moriyama and Yasuyuki Arakawa and Tatsuya Ide and Michio Sata and Osami Inoue and Masahiko Yano and Motohiko Tanaka and Shigetoshi Fujiyama and Shuhei Nishiguchi and Tetsuo Kuroki and Fumio Imazeki and Osamu Yokosuka and Shingo Kinoyama and Gotaro Yamada and Masao Omata},
  journal={Annals of internal medicine},
  year={1999},
  volume={131 3},
  pages={174-81}
}
BACKGROUND Previous studies on the effect of interferon therapy on the incidence of hepatocellular carcinoma have not sufficiently assessed degree of liver fibrosis, a major risk factor for hepatocellular carcinoma. OBJECTIVE To evaluate the effect of interferon therapy on incidence of hepatocellular carcinoma, adjusting for risk factors, including the degree of liver fibrosis. DESIGN Retrospective cohort study. SETTING Seven university hospitals and one regional core hospital in Japan… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS